Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 2
I'm long on ARCT. It looks like they are pursuing a similar track as Dyadic. Recombinant flu vaccines might be the next "big thing". As opposed to tradition vaccines, they do not require having to grow a vaccine virus sample. Recombinant vaccines are created synthetically and require dramatically less sample per dose. As a result, manufacturing capacity could be ramped up very quickly.

Barrons recently made this mention of ARCT:

"San Diego-based Arcturus Therapeutics Holdings (ARCT) has been a dark horse in the RNA vaccine race. This week, scientists at Singapore’s Duke-NUS Medical School said that they’ll start clinical trials of the company’s Covid vaccine in the city-state in August.

If the vaccine succeeds, Arcturus has a deal with Catalent (CTLT) for production. Hopes for the vaccine and other products have moved H.C. Wainright analyst Ed Arce to rate Arcturus a Buy. Recently trading at $37, the stock could hit $62, he thinks."
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.